Are we adequately considering drug interactions when prescribing statins to patients on cART with dyslipidaemia?

被引：0
|
作者：
Myers, J. [1 ]
Rayment, M. [1 ]
Sonecha, S. [1 ]
Moyle, G. [1 ]
Boffito, M. [1 ]
机构：
[1] Chelsea & Westminster Hosp, NHS Fdn Trust, London, England
来源：
HIV MEDICINE | 2009年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：33 / 34
页数：2
相关论文
共 46 条
  • [21] When good nutrients go bad: can we predict nutrient-drug interactions?
    Meckling, Kelly Anne
    BRITISH JOURNAL OF NUTRITION, 2009, 102 (03) : 334 - 336
  • [22] Opioid prescribing and risk of drug-opioid interactions in older discharged patients with polypharmacy in Australia
    Aymen Ali Al-Qurain
    Lemlem G. Gebremichael
    Mohammed S. Khan
    Desmond B. Williams
    Lorraine Mackenzie
    Craig Phillips
    Patrick Russell
    Michael S. Roberts
    Michael D. Wiese
    International Journal of Clinical Pharmacy, 2021, 43 : 365 - 374
  • [23] Opioid prescribing and risk of drug-opioid interactions in older discharged patients with polypharmacy in Australia
    Al-Qurain, Aymen Ali
    Gebremichael, Lemlem G.
    Khan, Mohammed S.
    Williams, Desmond B.
    Mackenzie, Lorraine
    Phillips, Craig
    Russell, Patrick
    Roberts, Michael S.
    Wiese, Michael D.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (02) : 365 - 374
  • [24] Potentially inappropriate medications, drug-drug interactions, and prescribing practices in elderly patients: a cross-sectional study
    Mugada, Vinodkumar
    Bhagavathi, Kusum Chandu
    Sagina, Poornima
    Karnataka, Kiranmai
    Ravada, Saritha
    Kancharapu, Ranjith Manohar
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2021, 67 (06): : 800 - 805
  • [25] Drug-drug interactions in hospitalized cancer patients: Are they common and how do we know them?
    Henri, L.
    Wertz, A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (06) : 1284 - 1285
  • [26] Consider clinically relevant pharmacokinetic drug interactions when co-prescribing drugs in attention-deficit/hyperactivity disorder
    Esther Kim
    Young-A. Heo
    Drugs & Therapy Perspectives, 2020, 36 : 386 - 388
  • [27] Consider clinically relevant pharmacokinetic drug interactions when co-prescribing drugs in attention-deficit/hyperactivity disorder
    Kim, Esther
    Heo, Young-A.
    DRUGS & THERAPY PERSPECTIVES, 2020, 36 (09) : 386 - 388
  • [28] What we need to know about drug interactions in patients with pulmonary arterial hypertension
    Wustmann, K.
    Schmidheiny, P.
    Schwerzmann, M.
    PROGRESS IN PEDIATRIC CARDIOLOGY, 2012, 34 (02) : 119 - 122
  • [29] Potential drug-drug interactions when managing status epilepticus patients in intensive care: A cohort study
    Le Roux, Clementine
    Destere, Alexandre
    Hervy, Sarah
    Lloret-Linares, Celia
    Reignier, Jean
    Caillet, Pascal
    Jolliet, Pascale
    Megarbane, Bruno
    Boels, David
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (05) : 2408 - 2418
  • [30] HOW CERTAIN ARE WE WHEN CONSIDERING THE OCCURRENCE OF GENITAL ULCERS AMONG ISRAELI ARAB FEMALE PATIENTS WITH BEHcETS DISEASE?
    Hassan, Fadi
    Hijazi, Nizar
    Naffaa, Mohammad E.
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2024, 26 (7-8): : 466 - 466
12345